SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jennifer A. Johnson, Paul E. Sax, Beginning Antiretroviral Therapy for Patients with HIV, Infectious Disease Clinics of North America, 2014, 28, 3, 421

    CrossRef

  2. 2
    H. Nina Kim, Carla V. Rodriguez, Stephen Van Rompaey, Joseph J. Eron, Chloe L. Thio, Heidi M. Crane, Edgar T. Overton, Michael S. Saag, Jeffrey Martin, Elvin Geng, Michael Mugavero, Benigno Rodriguez, W. Christopher Mathews, Stephen Boswell, Richard Moore, Mari M. Kitahata, Factors Associated With Delayed Hepatitis B Viral Suppression on Tenofovir Among Patients Coinfected With HBV-HIV in the CNICS Cohort, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2014, 66, 1, 96

    CrossRef

  3. 3
    J. S. Hafkin, M. K. Osborn, A. R. Localio, V. K. Amorosa, J. R. Kostman, J. J. Stern, P. Torre, K. Mounzer, I. Frank, R. Gross, K.-M. Chang, V. Lo Re, Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy, Journal of Viral Hepatitis, 2014, 21, 4
  4. 4
    Minhee Kang, Kimberly Hollabaugh, Vinh Pham, Susan L. Koletar, Kunling Wu, Marlene Smurzynski, Judith A. Aberg, Virologic and Serologic Outcomes of Mono vs. Dual HBV Therapy and Characterization of HIV/HBV Coinfection in a US Cohort, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2014, 1

    CrossRef

  5. 5
    Chao-ying Hu, Yan-mei Liu, Yun Liu, Qian Chen, Wei Wang, Kai Wu, Jie Dong, Jie Li, Jing-ying Jia, Chuan Lu, Shi-xuan Sun, Chen Yu, Xuening Li, Pharmacokinetics and Tolerability of Tenofovir Disoproxil Fumarate 300 mg Once Daily: An Open-Label, Single- and Multiple-Dose Study in Healthy Chinese Subjects, Clinical Therapeutics, 2013, 35, 12, 1884

    CrossRef

  6. 6
    The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans, Infection & Chemotherapy, 2013, 45, 4, 455

    CrossRef

  7. 7
    Maria C Segovia, Wadih Chacra, Stuart C Gordon, Adefovir dipivoxil in chronic hepatitis B: history and current uses, Expert Opinion on Pharmacotherapy, 2012, 13, 2, 245

    CrossRef

  8. 8
    Soon Sun Kim, Jae Youn Cheong, Dami Lee, Myoung Hee Lee, Sun Pyo Hong, Soo-Ok Kim, Sung Won Cho, Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B, Journal of Medical Virology, 2012, 84, 1
  9. 9
    Anders Boyd, Pierre-Marie Girard, Karine Lacombe, Consequences of persistent HBV infection in HIV: the double-edged sword of nucleos(t)ide analogs, Future Virology, 2012, 7, 2, 139

    CrossRef

  10. 10
    M. Nelson, G. Amaya, N. Clumeck, C. Arns da Cunha, D. Jayaweera, P. Junod, T. Li, P. Tebas, M. Stevens, A. Buelens, S. Vanveggel, K. Boven, Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials, Journal of Antimicrobial Chemotherapy, 2012, 67, 8, 2020

    CrossRef

  11. 11
    L. Kosi, T. Reiberger, B. A. Payer, K. Grabmeier-Pfistershammer, R. Strassl, A. Rieger, M. Peck-Radosavljevic, Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV–HIV-coinfected patients, Journal of Viral Hepatitis, 2012, 19, 11
  12. 12
    Olivier Lada, Anne Gervais, Michel Branger, Gilles Peytavin, Benedicte Roquebert, Gilles Collin, Gil Fraqueiro, Rami Moucari, Gwen Hamet, Michelle Martinot-Peignoux, Sophie Matheron, Patrick Marcellin, Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G, Liver International, 2012, 32, 1
  13. 13
    Andres F. Carrion, Paul Martin, Christopher O’Brien, Management of Patients with Chronic Hepatitis B Before and After Liver Transplantation: An Update, Current Hepatitis Reports, 2012, 11, 2, 102

    CrossRef

  14. 14
    J. A. Perez-Molina, M. Diaz-Menendez, M. N. Plana, J. Zamora, R. Lopez-Velez, S. Moreno, Very late initiation of HAART impairs treatment response at 48 and 96 weeks: results from a meta-analysis of randomized clinical trials, Journal of Antimicrobial Chemotherapy, 2012, 67, 2, 312

    CrossRef

  15. 15
    Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans, Infection and Chemotherapy, 2011, 43, 2, 89

    CrossRef

  16. 16
    Shu-Shan Zhao, Lan-Hua Tang, Xia-Hong Dai, Wei Wang, Rong-Rong Zhou, Li-Zhang Chen, Xue-Gong Fan, Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: A Systematic Review, Virology Journal, 2011, 8, 1, 111

    CrossRef

  17. 17
    Corinne Buchanan, Tram T. Tran, Current Status of Liver Transplantation for Hepatitis B Virus, Clinics in Liver Disease, 2011, 15, 4, 753

    CrossRef

  18. 18
    Chau-Ting Yeh, Tiffany Chen, Chao-Wei Hsu, Yi-Cheng Chen, Ming-Wei Lai, Kung-Hao Liang, Tse-Ching Chen, Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B, BMC Cancer, 2011, 11, 1, 398

    CrossRef

  19. 19
    Deepak Joshi, John O'Grady, Doug Dieterich, Brian Gazzard, Kosh Agarwal, Increasing burden of liver disease in patients with HIV infection, The Lancet, 2011, 377, 9772, 1198

    CrossRef

  20. 20
    Maria Mendes-Correa, João RR Pinho, Michele S Gomes-Gouvea, Adriana C da Silva, Cristina F Guastini, Luiz G Martins, Andréa G Leite, Mariliza H Silva, Reinaldo J Gianini, David E Uip, Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil, BMC Infectious Diseases, 2011, 11, 1, 247

    CrossRef

  21. 21
    Derek Yu, Jenny Heathcote, Tenofovir in the treatment of chronic hepatitis B, Therapy, 2011, 8, 5, 527

    CrossRef

  22. 22
    Vandana Khungar, Steven-Huy Han, A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B, Current Hepatitis Reports, 2010, 9, 2, 75

    CrossRef

  23. 23
    Mashu Aizawa, Akihito Tsubota, Kiyotaka Fujise, Tetsuro Kato, Mitsuo Sakamoto, Toshifumi Ohkusa, Hisao Tajiri, Highly active antiretroviral therapy improved persistent lamivudine-resistant viremia in acute hepatitis B virus genotype Ae infection with coinfection of human immunodeficiency virus, Hepatology Research, 2010, 40, 2
  24. 24
    K. Lacombe, J. Bottero, M. Lemoine, A. Boyd, P. M. Girard, HIV/hepatitis B virus co-infection: current challenges and new strategies, Journal of Antimicrobial Chemotherapy, 2010, 65, 1, 10

    CrossRef

  25. 25
    Florian van Bömmel, Robert A. de Man, Heiner Wedemeyer, Katja Deterding, Jörg Petersen, Peter Buggisch, Andreas Erhardt, Dietrich Hüppe, Kerstin Stein, Jörg Trojan, Christoph Sarrazin, Wulf O. Böcher, Ulrich Spengler, Hermann E. Wasmuth, Jurrien G.P. Reinders, Bernd Möller, Peter Rhode, Heinz-Hubert Feucht, Bertram Wiedenmann, Thomas Berg, Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues, Hepatology, 2010, 51, 1
  26. 26
    Helen Dakin, Carrie Fidler, Christie Harper, Mixed Treatment Comparison Meta-Analysis Evaluating the Relative Efficacy of Nucleos(t)ides for Treatment of Nucleos(t)ide-Naive Patients with Chronic Hepatitis B, Value in Health, 2010, 13, 8
  27. 27
    T. Asselah, O. Lada, P. Marcellin, Résultats des essais thérapeutiques dans l’hépatite chronique B, Antibiotiques, 2010, 12, 1, 42

    CrossRef

  28. 28
    Vincent Soriano, Eugenia Vispo, Pablo Labarga, Jose Medrano, Pablo Barreiro, Viral hepatitis and HIV co-infection, Antiviral Research, 2010, 85, 1, 303

    CrossRef

  29. 29
    David Cooper, Gail Matthews, Kucers' The Use of Antibiotics Sixth Edition, 2010,

    CrossRef

  30. 30
    Richard J. Whitley, Antibiotic and Chemotherapy, 2010,

    CrossRef

  31. 31
    Jorge L. Herrera, GI/Liver Secrets, 2010,

    CrossRef

  32. 32
    MARGARET JAMES KOZIEL, CHLOE LYNNE THIO, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  33. 33
    Brian Rha, David Kimberlin, Richard Whitley, Lennette's Laboratory Diagnosis of Viral Infections, 2010,

    CrossRef

  34. 34
    Erik De Clercq, Another ten stories in antiviral drug discovery (part C): “Old” and “new” antivirals, strategies, and perspectives, Medicinal Research Reviews, 2009, 29, 4
  35. 35
    Olivier Borgniet, Parviz Parvaz, Cécile Bouix, Philippe Chevallier, Christian Trépo, Patrice André, Fabien Zoulim, Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B, Journal of Medical Virology, 2009, 81, 8
  36. 36
    Martin Potter, Marina B Klein, Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B, HIV Therapy, 2009, 3, 2, 189

    CrossRef

  37. 37
    Sammy Saab, Maggie Y. Ham, Michael A. Stone, Curtis Holt, Myron Tong, Decision analysis model for hepatitis B prophylaxis one year after liver transplantation, Liver Transplantation, 2009, 15, 4
  38. 38
    Dennis J. Cada, Terri L. Levien, Danial E. Baker, Formulary Drug Reviews - Tenofovir Disoproxil Fumarate Tablets, Hospital Pharmacy, 2009, 44, 2, 165

    CrossRef

  39. 39
    David M Iser, Sharon R Lewin, Future directions in the treatment of HIV–HBV coinfection, HIV Therapy, 2009, 3, 4, 405

    CrossRef

  40. 40
    Melissa Osborn, Hepatitis B in HIV: Available treatment options and approach to therapy, Current Infectious Disease Reports, 2009, 11, 5, 407

    CrossRef

  41. 41
    M. Bahra, D. Seehofer, U.P. Neumann, T. Berg, Hepatitis-B- und -C-Reinfektion: Prophylaxe und Therapie, Der Gastroenterologe, 2009, 4, 6, 526

    CrossRef

  42. 42
    Man-Fung Yuen, James Fung, Danny Ka-Ho Wong, Ching-Lung Lai, Prevention and management of drug resistance for antihepatitis B treatment, The Lancet Infectious Diseases, 2009, 9, 4, 256

    CrossRef

  43. 43
    Robert J. Fontana, Side effects of long-term oral antiviral therapy for hepatitis B, Hepatology, 2009, 49, S5
  44. 44
    Caroline M. Perry, Dene Simpson, Tenofovir Disoproxil Fumarate, Drugs, 2009, 69, 16, 2245

    CrossRef

  45. 45
    Alice M. Jenh, Chloe L. Thio, Paul A. Pham, Tenofovir for the Treatment of Hepatitis B Virus, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009, 29, 10
  46. 46
    Elsa Marisol Pichardo, Sonja Olsen, Robert S. Brown, Viral hepatitis and renal failure, Current Hepatitis Reports, 2009, 8, 3, 119

    CrossRef

  47. 47
    Gail V. Matthews, Anchalee Avihingsanon, Sharon R. Lewin, Janaki Amin, Rungsun Rerknimitr, Panusit Petcharapirat, Pip Marks, Joe Sasadeusz, David A. Cooper, Scott Bowden, Stephen Locarnini, Kiat Ruxrungtham, Gregory J. Dore, A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand, Hepatology, 2008, 48, 4
  48. 48
    William Alazawi, Graham R Foster, Advances in the diagnosis and treatment of hepatitis B, Current Opinion in Infectious Diseases, 2008, 21, 5, 508

    CrossRef

  49. 49
    Vincent Soriano, Massimo Puoti, Marion Peters, Yves Benhamou, Mark Sulkowski, Fabien Zoulim, Stefan Mauss, Juergen Rockstroh, Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel, AIDS, 2008, 22, 12, 1399

    CrossRef

  50. 50
    Mari Inada, Osamu Yokosuka, Current antiviral therapies for chronic hepatitis B, Hepatology Research, 2008, 38, 6
  51. 51
    David M Iser, Joseph J Sasadeusz, Current treatment of HIV/hepatitis B virus coinfection, Journal of Gastroenterology and Hepatology, 2008, 23, 5
  52. 52
    Fabien Zoulim, Données actuelles sur le traitement de l’hépatite B chronique, La Presse Médicale, 2008, 37, 2, 287

    CrossRef

  53. 53
    Ellen Kitchell, Mamta K. Jain, Evaluation and treatment of the patient coinfected with hepatitis B and HIV, Current HIV/AIDS Reports, 2008, 5, 3, 103

    CrossRef

  54. 54
    Christoph Stephan, Experience with tenofovir disoproxil fumarate for antiretroviral therapy, Expert Opinion on Pharmacotherapy, 2008, 9, 7, 1197

    CrossRef

  55. 55
    Pablo Barreiro, Luz Martín-Carbonero, Javier García-Samaniego, Hepatitis B en pacientes con infección por el virus de la inmunodeficiencia humana, Enfermedades Infecciosas y Microbiología Clínica, 2008, 26, 71

    CrossRef

  56. 56
    Fabien Zoulim, Robert Perrillo, Hepatitis B: Reflections on the current approach to antiviral therapy, Journal of Hepatology, 2008, 48, S2

    CrossRef

  57. 57
    Megan Crane, Gail Matthews, Sharon R Lewin, Hepatitis virus immune restoration disease of the liver, Current Opinion in HIV and AIDS, 2008, 3, 4, 446

    CrossRef

  58. 58
    Anna S. F. Lok, How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting, Liver Transplantation, 2008, 14, S2
  59. 59
    J.-P. Zarski, V. Leroy, Le patient atteint d’hépatite chronique B non contrôlé, Gastroentérologie Clinique et Biologique, 2008, 32, 1, S7

    CrossRef

  60. 60
    Mark S. Sulkowski, Management of Hepatic Complications in HIV-Infected Persons, The Journal of Infectious Diseases, 2008, 197, s3, S279

    CrossRef

  61. 61
    Vincent Soriano, Eugenia Vispo, Marcelle Bottecchia, Julie Sheldon, Paula Tuma, Javier Garcia-Samaniego, Pablo Barreiro, Management of hepatitis B virus co-infection on and off antiretroviral therapy, Current HIV/AIDS Reports, 2008, 5, 2, 86

    CrossRef

  62. 62
    Fabien Zoulim, Sylvie Radenne, Christian Ducerf, Management of patients with decompensated hepatitis B virus associated cirrhosis, Liver Transplantation, 2008, 14, S2
  63. 63
    Bart Takkenberg, Joep de Bruijne, Christine Weegink, Peter Jansen, Hendrik Reesink, Novel therapies in hepatitis B and C, Current Gastroenterology Reports, 2008, 10, 1, 81

    CrossRef

  64. 64
    J.G.P. Reijnders, H.L.A. Janssen, Potency of tenofovir in chronic hepatitis B: Mono or combination therapy?, Journal of Hepatology, 2008, 48, 3, 383

    CrossRef

  65. 65
    Florian van Bömmel, Thomas Berg, Role of tenofovir in the treatment of chronic HBV infection, Future Virology, 2008, 3, 3, 207

    CrossRef

  66. 66
    Patrick Marcellin, E. Jenny Heathcote, Maria Buti, Ed Gane, Robert A. de Man, Zahary Krastev, George Germanidis, Sam S. Lee, Robert Flisiak, Kelly Kaita, Michael Manns, Iskren Kotzev, Konstantin Tchernev, Peter Buggisch, Frank Weilert, Oya Ovung Kurdas, Mitchell L. Shiffman, Huy Trinh, Mary Kay Washington, Jeff Sorbel, Jane Anderson, Andrea Snow-Lampart, Elsa Mondou, Joe Quinn, Franck Rousseau, Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B, New England Journal of Medicine, 2008, 359, 23, 2442

    CrossRef

  67. 67
    Jessica Tan, Bulent Degertekin, Stephen N. Wong, Munira Husain, Kelly Oberhelman, Anna S.F. Lok, Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations, Journal of Hepatology, 2008, 48, 3, 391

    CrossRef

  68. 68
    Marcelle Bottecchia, Javier Garcia-Samaniego, Vincent Soriano, The implications of antiviral drugs with activity against hepatitis B virus and HIV, Current Opinion in Internal Medicine, 2008, 7, 1, 57

    CrossRef

  69. 69
    F. Bailly, F. Zoulim, Traitement de l’hépatite B. Conduite thérapeutique, Gastroentérologie Clinique et Biologique, 2008, 32, 5, S172

    CrossRef

  70. 70
    T. Asselah, O. Lada, N. Boyer, M. Martinot, P. Marcellin, Traitement de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2008, 32, 8-9, 749

    CrossRef

  71. 71
    G. Carosi, M. Rizzetto, Treatment of chronic hepatitis B: Recommendations from an Italian workshop, Digestive and Liver Disease, 2008, 40, 8, 603

    CrossRef

  72. 72
    Bijal Surti, Amanda C. Chi, Sammy Saab, Update on management of hepatitis B before and after liver transplantation, Current Hepatitis Reports, 2008, 7, 1, 25

    CrossRef

  73. 73
    Bulent Degertekin, Anna SF Lok, Update on viral hepatitis: 2007, Current Opinion in Gastroenterology, 2008, 24, 3, 306

    CrossRef

  74. 74
    Bulent Degertekin, Anna SF Lok, Update on viral hepatitis: 2007, Current Opinion in Internal Medicine, 2008, 7, 4, 332

    CrossRef

  75. 75
    Mark S. Sulkowski, Viral hepatitis and HIV coinfection, Journal of Hepatology, 2008, 48, 2, 353

    CrossRef

  76. 76
    Anna S. F. Lok, Brian J. McMahon, Chronic hepatitis B, Hepatology, 2007, 45, 2
  77. 77
    Oliver Schildgen, Florian van Bömmel, Jürgen K Rockstroh, Current and future therapies for chronic HBV-infections, Reviews in Medical Microbiology, 2007, 18, 4, 79

    CrossRef

  78. 78
    Fabien Zoulim, Emerging drugs for hepatitis B, Expert Opinion on Emerging Drugs, 2007, 12, 2, 199

    CrossRef

  79. 79
    Lionel Piroth, Damien S??ne, Stanislas Pol, Isabelle Goderel, Karine Lacombe, Benoit Martha, David Rey, V??ronique Loustau-Ratti, Jean-Fran??ois Bergmann, Gilles Pialoux, Anne Gervais, Caroline Lascoux-Combe, Fabrice Carrat, Patrice Cacoub, Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY), AIDS, 2007, 21, 10, 1323

    CrossRef

  80. 80
    Yves Benhamou, Hepatitis B in the HIV-Coinfected Patient, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2007, 45, Supplement 2, S57

    CrossRef

  81. 81
    Kenneth E. Sherman, Marion Peters, Margaret James Koziel, HIV and liver disease forum: Conference proceedings, Hepatology, 2007, 45, 6
  82. 82
    P. Miailhes, M.-A. Trabaud, P. Pradat, B. Lebouche, M. l. Chevallier, P. Chevallier, F. Zoulim, C. Trepo, Impact of Highly Active Antiretroviral Therapy (HAART) on the Natural History of Hepatitis B Virus (HBV) and HIV Coinfection: Relationship between Prolonged Efficacy of HAART and HBV Surface and Early Antigen Seroconversion, Clinical Infectious Diseases, 2007, 45, 5, 624

    CrossRef

  83. 83
    Kwan Sik Lee, Dong Joon Kim, Management of Chronic Hepatitis B, The Korean Journal of Hepatology, 2007, 13, 4, 447

    CrossRef

  84. 84
    Jay H. Hoofnagle, Edward Doo, T. Jake Liang, Russell Fleischer, Anna S.F. Lok, Management of hepatitis B: Summary of a clinical research workshop, Hepatology, 2007, 45, 4
  85. 85
    Anna Suk–Fong Lok, Navigating the Maze of Hepatitis B Treatments, Gastroenterology, 2007, 132, 4, 1586

    CrossRef

  86. 86
    Albert D. Min, Jules L. Dienstag, Oral Antivirals for Chronic Hepatitis B, Clinics in Liver Disease, 2007, 11, 4, 851

    CrossRef

  87. 87
    Melissa K. Osborn, Steven H. Han, Arie Regev, Natalie H. Bzowej, Michael B. Ishitani, Tram T. Tran, Anna S.F. Lok, Outcomes of Patients With Hepatitis B Who Developed Antiviral Resistance While on the Liver Transplant Waiting List, Clinical Gastroenterology and Hepatology, 2007, 5, 12, 1454

    CrossRef

  88. 88
    J. I. Tsui, A. L. French, E. C. Seaberg, M. Augenbraun, M. Nowicki, M. Peters, P. C. Tien, Prevalence and Long-Term Effects of Occult Hepatitis B Virus Infection in HIV-Infected Women, Clinical Infectious Diseases, 2007, 45, 6, 736

    CrossRef

  89. 89
    Patrice Cacoub, Lionel Piroth, Prise en charge des malades coinfectés VIH-VHC et VIH-VHB, Gastroentérologie Clinique et Biologique, 2007, 31, 10, 887

    CrossRef

  90. 90
    David J Quan, Marion G Peters, Tenofovir disoproxil fumarate for the treatment of hepatitis B virus infection: pharmacokinetics and clinical efficacy, Therapy, 2007, 4, 2, 141

    CrossRef

  91. 91
    Srinivas Cheruvu, Kristen Marks, Andrew H. Talal, Understanding the Pathogenesis and Management of Hepatitis B/HIV and Hepatitis B/Hepatitis C Virus Coinfection, Clinics in Liver Disease, 2007, 11, 4, 917

    CrossRef

  92. 92
    Margaret James Koziel, Marion G. Peters, Viral Hepatitis in HIV Infection, New England Journal of Medicine, 2007, 356, 14, 1445

    CrossRef

  93. 93
    Erik De Clercq, Discovery and Development of Tenofovir Disoproxil Fumarate,
  94. 94
    Marion G. Peters, Vincent Soriano, HIV and the Liver,